REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
即将进行的临床试验
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied Practice尚未招聘
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLC尚未招聘
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata Verona尚未招聘
-
University of Wisconsin, MadisonAlkermes, Inc.尚未招聘
-
Virginia Commonwealth University尚未招聘
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount Sinai尚未招聘氯胺酮 | 功能磁共振成像 | 抑郁症 - 重度抑郁症 | 经颅磁刺激 | 难治性抑郁症 (TRD)美国
-
Weill Medical College of Cornell UniversityBD2 LLC尚未招聘功能磁共振成像 | 双相情感障碍 (BD) | 经颅磁刺激 | 双极 1 抑郁症美国
-
Yale UniversityNational Institute of Mental Health (NIMH)尚未招聘
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge招聘中嗜铬细胞瘤 | 嗜铬细胞瘤/副神经节瘤 | 嗜铬细胞瘤,转移性 | 嗜铬细胞瘤恶性 | 嗜铬细胞瘤和paraganglioma(PPGL)英国
-
Carl Zeiss Meditec-Dublin CoCe招聘中视网膜前膜 | 视网膜疾病 | 干性年龄相关性黄斑变性 | 玻璃体视网膜异常 | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium (RPE) Atrophy美国
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical University招聘中